Supernus Pharmaceuticals, Inc. (SUPN)
29.72
+0.52
(+1.78%)
USD |
NASDAQ |
Nov 13, 16:00
29.30
-0.42
(-1.41%)
After-Hours: 19:59
Supernus Pharmaceuticals Enterprise Value : 1.408B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 1.408B |
| November 12, 2026 | 1.378B |
| November 11, 2026 | 1.392B |
| November 10, 2026 | 1.352B |
| November 09, 2026 | 1.286B |
| November 06, 2026 | 1.201B |
| November 05, 2026 | 1.234B |
| November 04, 2026 | 1.320B |
| November 03, 2026 | 1.317B |
| November 02, 2026 | 1.790B |
| October 30, 2026 | 2.119B |
| October 29, 2026 | 2.114B |
| October 28, 2026 | 2.070B |
| October 27, 2026 | 2.063B |
| October 26, 2026 | 2.052B |
| October 23, 2026 | 2.048B |
| October 22, 2026 | 2.127B |
| October 21, 2026 | 2.077B |
| October 20, 2026 | 2.079B |
| October 19, 2026 | 1.998B |
| October 16, 2026 | 1.883B |
| October 15, 2026 | 1.982B |
| October 14, 2026 | 2.017B |
| October 13, 2026 | 2.124B |
| October 12, 2026 | 2.171B |
| Date | Value |
|---|---|
| October 09, 2026 | 2.162B |
| October 08, 2026 | 2.132B |
| October 07, 2026 | 2.185B |
| October 06, 2026 | 2.172B |
| October 05, 2026 | 2.168B |
| October 02, 2026 | 2.146B |
| October 01, 2026 | 2.134B |
| September 30, 2026 | 2.184B |
| September 29, 2026 | 2.226B |
| September 28, 2026 | 2.262B |
| September 25, 2026 | 2.149B |
| September 24, 2026 | 2.186B |
| September 23, 2026 | 2.192B |
| September 22, 2026 | 2.213B |
| September 21, 2026 | 2.156B |
| September 18, 2026 | 2.111B |
| September 17, 2026 | 2.165B |
| September 16, 2026 | 2.075B |
| September 15, 2026 | 2.069B |
| September 14, 2026 | 2.081B |
| September 11, 2026 | 2.090B |
| September 10, 2026 | 2.093B |
| September 09, 2026 | 2.115B |
| September 08, 2026 | 2.136B |
| September 04, 2026 | 2.200B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.807B |
| Prestige Consumer Healthcare, Inc. | 4.270B |
| Structure Therapeutics, Inc. | 194.14M |
| Corcept Therapeutics, Inc. | 7.615B |
| Veru, Inc. | 12.53M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 20.91M |
| Revenue (Quarterly) | 226.77M |
| Total Expenses (Quarterly) | 205.86M |
| EPS Diluted (Quarterly) | 0.3516 |
| Gross Profit Margin (Quarterly) | 77.67% |
| Profit Margin (Quarterly) | 9.22% |
| Earnings Yield | -2.57% |
| Operating Earnings Yield | 0.77% |
| Normalized Earnings Yield | -0.0306 |